Autologous Dendritic Cell Vaccine Optimization for Therapy of Patients with Disseminated Malignant Ne
Immunobiological features of the dendritic cells (DC) were studied for the production of DC-vaccine (DCV) optimization. DC were differentiated in vitro in GM-CSF (previously studied concentration 72 ng/ml and IL-4 0–45 ng/ml containing medium. GM-CSF compounds by Pharmsynthez (Russia) and Cell Genix...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2016-02-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/131 |
| Summary: | Immunobiological features of the dendritic cells (DC) were studied for the production of DC-vaccine (DCV) optimization. DC were differentiated in vitro in GM-CSF (previously studied concentration 72 ng/ml and IL-4 0–45 ng/ml containing medium. GM-CSF compounds by Pharmsynthez (Russia) and Cell Genix (Germany) and IL-4 by Cell Genix (Germany) were used. Comparative assays of mature and immature DC immunophenotype using different GM-CSF compounds was performed. CD1а, CD83, CD86, CD80, CCR7 и HLA DR are recommended optimal markers of DC for the standardization of technologic process. Flow cytometry and immunocytochemistry assays revealed no differences in mature DC markers expression (p>0,05). This indicates the expediency of Pharmsynthez (Russia) GM-CSF usage for DCV production. Optimal IL-4 concentrations (5–15 ng/ml) providing qualitative characteristics for DCV production were found using second level one-way polynomial model. |
|---|---|
| ISSN: | 1814-4861 2312-3168 |